HomeSYNGENE › Filing
🔔 Get instant alerts when SYNGENE files quarterly results on BSE Start free trial →

Outcome of Board Meeting

Filed: 29 Jul 2026, 17:36 IST Exchange: NSE Category: Financial Results — Audited Results
Q1FY27 results (unaudited): Standalone: Revenue 8.7bn -16% y-y (10.4bn) PAT 0.9bn -41% y-y (1.5bn) Consolidated: Revenue 8.0bn -17% y-y (9.6bn) PAT 0.7bn -50% y-y (1.5bn) FY26 results (audited): Standalone: Revenue 38.1bn +2% y-y (37.4bn) EBITDA 8.5bn +5% y-y (8.1bn) EBITDA margin 22.3% (21.9%) +40 bps y-y PAT 3.2bn +7% y-y (3.0bn) Consolidated: Revenue 34.9bn +2% y-y (34.2bn) EBITDA 7.6bn +5% y-y (7.3bn) EBITDA margin 21.7% (21.4%) +30 bps y-y PAT 3.0bn +7% y-y (2.8bn) Dividend: Rs 1.25/share (recommended, subject to AGM approval) Commentary: Exceptional items include termination benefits and labour code impacts; subsidiary Syngene Manufacturing Solutions Limited is in voluntary liquidation.
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 SYNGENE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add SYNGENE to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Syngene International Limited

Important. The summary above is generated automatically from Syngene International Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.